Radiotherapy for patients with locoregional and oligometastatic relapses of prostate cancer after radical prostatectomy

Materials and methods. In our study, 21 patients with recurrent prostate cancer after radical prostatectomy and oligometastases were treated by salvage radiation therapy, which included radiotherapy treatment of recurrent tumors, regional pelvic lymph nodes, the prostate bed and stereotactic body radiation therapy to detected solitary metastases.
Results. The average follow-up period was 19 ± 3.5 months. At the same time, 12 (57 %) of 21 patients are currently under observation for more than 1 year, and 1 patient for more than 5 years without signs of a biochemical recurrence. The indicator of biochemical control of the disease was 86 % (18 / 21 patients) with an average follow-up period of 19 months.
Conclusion. It seems to us that further study of this problem can replace today's palliative standard of treatment for this special category of patients — hormonal and chemotherapy treatment, which has low effectiveness at a high incidence of toxicity.

1. State of oncological care in Russia in 2017. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2018. 236 p. (In Russ.).

2. Briganti A., Karnes R.J., Gandaglia G. et al. Natural history of surgically treated high-risk prostate canсer. Urol Oncol 2015;33(4):163.e7.

3. Makarov D.V., Trock B.J., Humphreys E.B. et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate - specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69(6):1095-101. DOI: 10.1016/j.eururo.2007.08.010.

4. Joniau S., Hsu C.Y., Lerut E. et al. A pretreatment table for the prediction of final histopothology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007;51(2):388-96. DOI: 10.1016/j.eururo.2006.06.051.

5. Cookson M.S., Aus G., Burnett A.L. et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer. The American Urological Association Prostate Guidelines for Localized Prostate Cancer. Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes. J Urol 2007;177:540-5. DOI: 10.1016/j.juro.2006.10.097.

6. Boccon-Gibod L., Djavan W.B., Hammerer P. Management of prostatespecific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004;58(4):382-90. DOI: 10.1111/j.1368-5031.2004.00184.x.

7. Sciara A., Panebianco V., Calciccia S. Role of dynamic contrast-enchanced magnetic resonance (MRI) imaging and proton MR spectroscopic imaging in the detection of local racurrence after radical prostatectomy for prostate cancer. Eur Urol 2008;54:589-600. DOI: 10.1016/j.eururo.2007.12.034.

8. Cirillo S., Petracchini M., Scotti L. et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assesslocal recurrence following radical prostatectomyusing T2-weighted and contrast-enhanced imaging. Eur Radiol 2009;19(3):761-9. DOI: 10.1007/s00330-008-1174-8.

9. Akhverdieva G.I. Topical MRI diagnostics of localized prostate cancer and its recurrence after radical prostatectomy. Author's abstract. ... candidate of medical sciences: 14.01.13. Moscow, 2014. 126 p. (In Russ.).

10. Liauw S.L., Pitroda S.P., Eggener S.E. et al. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonanceimaging. Int J Radiat Oncol Biol Phys 2013;85(2):378-84. DOI: 10.1016/j.ijrobp.2012.05.015.

11. Linder B.J., Kawashima A., Woodrum D.A. et al. Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging. Can J Urol 2014;21(3):7283-9.

12. Коссов Ф.А., Булычкин П.В., Олимов Б.П. и др. Возможности муль-типараметрической магнитно-резонансной томографии в персонализации «спасительной» лучевой терапии у больных с рецидивом рака предстательной железы. Вестник рентгенологии и радиологии 2018;99(2):91.

13. Perner S., Hofer M.D., Kim R. et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007;38:696-701. DOI: 10.1016/j.humpath.2006.11.012.

14. Eiber M., Maurer T., Souvatzoglou M. et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015;56:668-74. DOI: 10.2967/jnumed.115.154153.

15. Morigi J.J., Stricker P.D., Van Leeuwen P.J. et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015;56:1185-90. DOI: 10.2967/jnumed.115.160382.

16. Tkachev S.I., Bulychkin P.V., Berdnik A.V. et al. Hypofractionated salvage radiation therapy for patients with recurrence prostate cancer after radical prostatectomy. Meditsinskaya radiologiya i radiatsionnaya bezopasnost' = Medical Radiology and Radiation Safety 2014;(6):43-8. (In Russ.)

17. Tkachev S.I., Bulychkin P.V., Mikhailova A.V. et al. Salvage radiotherapy after radical prostatectomy in mode of hypofractionation. Voprosy oncologii = Oncology Issues 2015;(5):782-4. (In Russ.).

18. Tkachev S.I., Bulychkin P.V., Matveev V.B. et al. Salvage radiotherapy of prostate cancer recurrences after radical prostatectomy. Onkourologiya = Cancer Urology 2018;14(1):100-6. (In Russ.).

19. Bulychkin P.V., Tkachev S.I., Matveev V.B., Nazarenko A.V. Prostatespecific antigen is a predictor of the efficacy of salvage radiation therapy in patients with recurrent prostate cancer after radical prostatectomy. Onkourologiya = Cancer Urology 2019;15(2):66-72. (In Russ.).

20. Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol 1995;13(1):8-10. DOI: 10.1200/JCO.1995.13.1.8.

21. Yao H.H., Hong M.Kh., Corcoran N.M. et al. Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia Pac J Clin Oncol 2014;10(4):308-21. DOI: 10.1111/ajco.12256.